Louis Siegel, DO
Pediatric Dermatology · Valley Stream, NYNPI 1922363605
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $447 of the $547 with a category attached, or 81.7%. 12 manufacturers reported payments, led by Johnson & Johnson at 33.2% of the total.
Across 25 payments — averaging $21.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$181
- Galderma Laboratories, L.p.$88
- Merck$66
- AbbVie$51
- Pfizer$32
- Incyte Corporation$23
- plus $105 from 6 others
What the payments were for
- Food & beverage$44782%
- Education$10018%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 5 | $181 |
| Galderma Laboratories, L.p. | 4 | $88 |
| Merck | 4 | $66 |
| AbbVie | 3 | $51 |
| Pfizer | 2 | $32 |
| Incyte Corporation | 1 | $23 |
| Bayer | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Novo Nordisk | 1 | $18 |
| Shield Therapeutics Inc | 1 | $16 |
| Biofrontera Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
How this compares
Too few pediatric dermatology providers in New Yorkto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 32 | $130,981 |
| Dupixent SyringeDupilumab | 15 | $64,168 |
| Tacrolimus | 73 | $14,955 |
| Acitretin | 18 | $8,271 |
| Clindamycin Phosphate | 72 | $3,337 |
| Fluocinonide | 59 | $3,288 |
| Clobetasol Propionate | 76 | $3,071 |
| Azelaic Acid | 20 | $2,891 |
| Ketoconazole | 157 | $2,757 |
| Fluorouracil | 28 | $1,672 |
| Mometasone Furoate | 75 | $1,556 |
| Tretinoin | 33 | $1,393 |
| Metronidazole | 30 | $1,282 |
| Triamcinolone Acetonide | 114 | $1,008 |
| CiclopiroxCiclopirox Olamine | 30 | $789 |
Paid to pharmacies, not to this prescriber.
Other pediatric dermatology in Valley Stream
- Seth OrlowNew York$309K
- Vikash OzaNew York$80K
- Leonard KristalEast Setauket$37K
- Sharon GlickBrooklyn$14K
- Christine LaurenNew York$7K
- Justine BiedermanNew York$7K
- Alexis PerlmutterDelmar$4K
- Karen ChernoffNew York$3K
- Lauren GellerPurchase$982
- Brook TlouganScarsdale$614
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.